We’re excited to share that we are establishing a collaboration with Stanford GMP Facility: Laboratory for Cell and Gene Medicine(LCGM) to deploy our robotic systems for cell therapy manufacturing!

Combining LCGM’s unmatched process development expertise with our robotic technology enables cell therapy organizations to run side-by-side comparisons of their current manual processes with the corresponding automated processes. We can’t wait for cell therapy leaders to see what’s possible with automation as we take another step forward to reducing barriers to patient access to cell therapies.

We’re excited to announce that we’ve partnered with GenScript to automate the cell isolation and enrichment phase of cell therapy manufacturing!

Cell isolation using immunomagnetic beads is a critical industry-standard process in cell therapy manufacturing. However, this task is complex and very time-consuming when done manually. Using our cell therapy robotic cluster and GenScript’s GMP-grade CytoSinct 1000 cell isolation solution, this collaboration will introduce the first fully automated solution for bead-based cell isolation.

By incorporating this technology, cell therapy manufacturers can automate this part of the process without making substantial modifications to their original manufacturing processes. Automation in this deeply time-consuming area of the process will drive significant benefits around efficiency and support the scalability of cell therapies.

We’ve teamed up with Wilson Wolf Manufacturing, LLC to automate their G-Rex® bioreactors! This partnership is driven by our mutual goal to simplify and reduce costs for cell therapy manufacturing.

G-Rex® bioreactors are already extensively used for cell therapy manufacturing today, which means manufacturers can use the automated G-Rex® bioreactor without substantially changing their existing process. This collaboration takes us one step closer to fully automated cell therapy manufacturing, ultimately reducing barriers to access to these life-saving therapies.

Shanghai, China, December 1st, 2022 – WuXi STA, a subsidiary of WuXi AppTec and a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the partnership with Multiply Labs (based in San Francisco, CA, USA), a robotics company that has developed industry-leading automated manufacturing systems to produce individualized drugs.

The focus of the partnership is to enable the manufacturing of personalized drugs for patients.
Within this collaboration, Multiply Labs has deployed a novel robotic system in WuXi STA’s facilities that efficiently produces advanced solid oral dosage forms, including capsules containing personalized dosage strengths of a single API (e.g., for modified release) and capsules containing personalized combinations of multiple APIs and their formulations. This robotic technology targets a broad range of GMP manufacturing applications, including the production of personalized drug products for specific patient groups (e.g., pediatric/geriatric populations and rare disease patients) and the combination of multiple drugs in one single capsule (e.g., for personalized combination therapies).

Personalized dosing applications – from clinical to commercial manufacturing – have traditionally been very challenging and labor-intensive. Truly personalized manufacturing is limited by the inflexibility of traditional manufacturing technologies, which are only able to generate one large batch each time. The WuXi STA – Multiply Labs partnership addresses these challenges through the unique combination of robotic technology and drug product manufacturing expertise.

As part of the partnership, Multiply Labs has completed the deployment of a robotic system in WuXi STA’s drug product manufacturing site in Wuxi city, China. The manufacturing applications of the robotic system focuses on the development and GMP manufacturing of capsules with personalized doses.

This technology can manufacture virtually any type of capsules, and even capsule configurations that are difficult with traditional technologies. The robots have been designed to handle personalized deposition for most common formulations, including powders, powder blends, granules, beads, and minitabs. The system can be preprogrammed to manufacture personalized product batches – for example, different dosage strengths for different patients, different release profiles for better therapeutic effects, dosage form flexibility such as minitabs vs granule, etc., giving customers the enhanced flexibility. In addition to traditional capsules, this robotic system can also manufacture multi-compartment capsules, which are ideal for drug combinations where two or more APIs or formulations need to be compartmentalized.

 “WuXi STA is a globally recognized leader in the formulation development and manufacturing, and Multiply Labs is excited to partner with them in bringing our pioneering robotic technology to the market,” said Fred Parietti, Ph.D., Co-founder, and CEO of Multiply Labs. “Our joint teams have collaborated at an unprecedented speed to develop and deploy this unique technology. Our goal is to enable precision medicine to scale and reach all the patients who need it, and this breakthrough partnership is an exciting step forward towards that vision.”

“We believe that automation is the future of pharmaceutical manufacturing,” said Jinling Chen, Ph.D., SVP and Head of Pharmaceutical Development and Manufacturing Services at WuXi STA. “By bringing together Multiply Labs’ novel robotic technology and WuXi STA’s industry-leading drug product development and manufacturing expertise, we can better support customers to accelerate their drug product development by enabling more personalized dosing for clinical studies.”